Laura J Wozniak1, Michelle J Hickey, Robert S Venick, Jorge H Vargas, Douglas G Farmer, Ronald W Busuttil, Sue V McDiarmid, Elaine F Reed. 1. 1 Pediatric Gastroenterology, Hepatology, and Nutrition, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA. 2 Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA. 3 Immunogenetics Center, University of California, Los Angeles, Los Angeles, CA. 4 Division of Liver and Pancreas Transplantation, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA.
Abstract
BACKGROUND: The role of donor-specific HLA antibodies (DSA) after pediatric liver transplantation (LTx) is not clearly established. We completed a cross-sectional study to characterize DSA in long-term survivors of pediatric LTx and assess the impact of C1q-binding DSA on allograft outcomes. METHODS: Serum samples were collected at routine clinic visits from 50 pediatric LTx recipients classified into 3 clinical phenotypes: nontolerant (n = 18) with de novo autoimmune hepatitis (DAIH) and/or late acute cellular rejection (ACR); stable (n = 25) on maintenance tacrolimus; operationally tolerant (n = 7). Samples were blinded, and antibody detection was performed using Luminex single antigen class I and II beads. Patients with positive DSA were tested for C1q-binding DSA. RESULTS: DSA were detected in 54% (n = 27) of the patients, with the majority directed at HLA class II antigens (DR, 41%; DQ, 53%). Patients with DSA were younger at the time of LTx (P = 0.016) and time of study (P = 0.024). Mean aspartate aminotransferase, alanine aminotransferase, total bilirubin, and gamma glutamyl transferase were higher in DSA-positive patients, though did not reach statistical significance. Nontolerant patients were significantly more likely to have DQ DSA (61%) compared to stable (20%) and tolerant (29%) patients (P = 0.021). The nontolerant phenotype was associated with DSA and C1q-binding DSA, with odds ratios of 13 (P = 0.015) and 8.6 (P = 0.006), respectively. The presence of DQ DSA was associated with DAIH and late ACR, with odds ratios of 12.5 (P = 0.004) and 10.8 (P = 0.006), respectively. CONCLUSIONS: Allograft dysfunction is not always evident in patients with DSA, but DQ DSA are strongly associated with DAIH, late ACR, and chronic rejection.
BACKGROUND: The role of donor-specific HLA antibodies (DSA) after pediatric liver transplantation (LTx) is not clearly established. We completed a cross-sectional study to characterize DSA in long-term survivors of pediatric LTx and assess the impact of C1q-binding DSA on allograft outcomes. METHODS: Serum samples were collected at routine clinic visits from 50 pediatric LTx recipients classified into 3 clinical phenotypes: nontolerant (n = 18) with de novo autoimmune hepatitis (DAIH) and/or late acute cellular rejection (ACR); stable (n = 25) on maintenance tacrolimus; operationally tolerant (n = 7). Samples were blinded, and antibody detection was performed using Luminex single antigen class I and II beads. Patients with positive DSA were tested for C1q-binding DSA. RESULTS:DSA were detected in 54% (n = 27) of the patients, with the majority directed at HLA class II antigens (DR, 41%; DQ, 53%). Patients with DSA were younger at the time of LTx (P = 0.016) and time of study (P = 0.024). Mean aspartate aminotransferase, alanine aminotransferase, total bilirubin, and gamma glutamyl transferase were higher in DSA-positive patients, though did not reach statistical significance. Nontolerant patients were significantly more likely to have DQ DSA (61%) compared to stable (20%) and tolerant (29%) patients (P = 0.021). The nontolerant phenotype was associated with DSA and C1q-binding DSA, with odds ratios of 13 (P = 0.015) and 8.6 (P = 0.006), respectively. The presence of DQ DSA was associated with DAIH and late ACR, with odds ratios of 12.5 (P = 0.004) and 10.8 (P = 0.006), respectively. CONCLUSIONS: Allograft dysfunction is not always evident in patients with DSA, but DQ DSA are strongly associated with DAIH, late ACR, and chronic rejection.
Authors: Adriana Zeevi; John Lunz; Brian Feingold; Michael Shullo; Christian Bermudez; Jeffery Teuteberg; Steven Webber Journal: J Heart Lung Transplant Date: 2012-11-09 Impact factor: 10.247
Authors: J D Smith; N R Banner; I M Hamour; M Ozawa; A Goh; D Robinson; P I Terasaki; M L Rose Journal: Am J Transplant Date: 2011-01-10 Impact factor: 8.086
Authors: A Del Bello; N Congy-Jolivet; F Muscari; L Lavayssière; L Esposito; I Cardeau-Desangles; J Guitard; G Dörr; B Suc; J P Duffas; L Alric; C Bureau; M Danjoux; C Guilbeau-Frugier; A Blancher; L Rostaing; N Kamar Journal: Am J Transplant Date: 2014-03-01 Impact factor: 8.086
Authors: R S Venick; S V McDiarmid; D G Farmer; J Gornbein; M G Martin; J H Vargas; M E Ament; R W Busuttil Journal: Am J Transplant Date: 2007-04 Impact factor: 8.086
Authors: Ranka Vukotic; Giovanni Vitale; Antonia D'Errico-Grigioni; Luigi Muratori; Pietro Andreone Journal: World J Gastroenterol Date: 2016-03-14 Impact factor: 5.742
Authors: Sandy Feng; Anthony J Demetris; Katharine M Spain; Sai Kanaparthi; Bryna E Burrell; Udeme D Ekong; Estella M Alonso; Philip Rosenthal; Laurence A Turka; David Ikle; Nadia K Tchao Journal: Hepatology Date: 2016-07-27 Impact factor: 17.425
Authors: Sandy Feng; John C Bucuvalas; Anthony J Demetris; Bryna E Burrell; Katherine M Spain; Sai Kanaparthi; John C Magee; David Ikle; Andrew Lesniak; Juan J Lozano; Estella M Alonso; Robert A Bray; Nancy E Bridges; Edward Doo; Howard M Gebel; Nitika A Gupta; Ryan W Himes; Annette M Jackson; Steven J Lobritto; George V Mazariegos; Vicky L Ng; Elizabeth B Rand; Averell H Sherker; Shikha Sundaram; Yumirle P Turmelle; Alberto Sanchez-Fueyo Journal: Gastroenterology Date: 2018-08-23 Impact factor: 22.682
Authors: Adam S Arterbery; Awo Osafo-Addo; Yaron Avitzur; Maria Ciarleglio; Yanhong Deng; Steven J Lobritto; Mercedes Martinez; David A Hafler; Markus Kleinewietfeld; Udeme D Ekong Journal: J Immunol Date: 2016-04-18 Impact factor: 5.422